Global Gene Therapy On Cardiovascular Disease Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027
Executive Summary
According to GRD Survey data, the global Gene Therapy On Cardiovascular Disease market was valued at million US$ in 2020 and is expected to million US$ by the end of 2027, growing at a CAGR of % in the forecast period 2021 and 2027.
This report studies the Gene Therapy On Cardiovascular Disease market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Gene Therapy On Cardiovascular Disease in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)
Market Snapshot, By Product Type
Viral Gene Therapy
Non-Viral Gene Therapy
Market Snapshot, By Application
Heart Disease
Vascular Disease
Market Snapshot, By Region:
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
South Africa
Israel
Turkey
Saudi Arabia
Main Market Players Analyzed in this report, including:
Sunway Biotech
Spark Therapeutics
SIBIONO
Sarepta Therapeutics
Orchard Therapeutics
Novartis
Human Stem Cells Institute
Gilead Sciences
bluebird bio
Biogen
AnGes
Amgen
Alnylam Pharmaceuticals
Akcea Therapeutics
The study objectives of this report are:
To study and analyze the global Gene Therapy On Cardiovascular Disease market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Gene Therapy On Cardiovascular Disease market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Gene Therapy On Cardiovascular Disease manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Gene Therapy On Cardiovascular Disease market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Gene Therapy On Cardiovascular Disease submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Gene Therapy On Cardiovascular Disease are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027
This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries
Table of Contents
1 Market Definition & Scope
1.1 Definition & Scope
1.2 Gene Therapy On Cardiovascular Disease Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Gene Therapy On Cardiovascular Disease Market Performance and Outlook
2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter's Five Forces Analysis
2.3 Comparison of Alternatives and Gene Therapy On Cardiovascular Disease
3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Gene Therapy On Cardiovascular Disease Sales Channel and Distributors Analysis
3.3.1 Gene Therapy On Cardiovascular Disease Sales Channel
3.3.2 Gene Therapy On Cardiovascular Disease Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Application One
3.4.2 Major Buyers in Application Two
3.4.1 Major Buyers in Application Three
3.5 Gene Therapy On Cardiovascular Disease Manufacturing Cost Structure Analysis
4 Market Segment: by Type
4.1 Gene Therapy On Cardiovascular Disease Type Introduction
4.1.1 Viral Gene Therapy
4.1.2 Non-Viral Gene Therapy
4.2 Global Gene Therapy On Cardiovascular Disease Sales by Type 2016-2021
4.3 Global Gene Therapy On Cardiovascular Disease Revenue by Type 2016-2021
4.4 Global Gene Therapy On Cardiovascular Disease Price by Type 2016-2021
5 Market Segment: by Application
5.1 Gene Therapy On Cardiovascular Disease Type Introduction
5.1.1 Heart Disease
5.1.2 Vascular Disease
5.2 Global Gene Therapy On Cardiovascular Disease Sales by Application 2016-2021
5.3 Global Gene Therapy On Cardiovascular Disease Revenue by Application 2016-2021
5.4 Global Gene Therapy On Cardiovascular Disease Price by Application 2016-2021
6 Marke Segment: by Region
6.1 Global Gene Therapy On Cardiovascular Disease Market by Region
6.1.1 Global Gene Therapy On Cardiovascular Disease Sales by Regions
6.1.2 Global Gene Therapy On Cardiovascular Disease Revenue by Regions
6.2 North America Gene Therapy On Cardiovascular Disease Market 2016-2021
6.3 Europe Gene Therapy On Cardiovascular Disease Market 2016-2021
6.4 Asia Pacific Gene Therapy On Cardiovascular Disease Market 2016-2021
6.5 South America Gene Therapy On Cardiovascular Disease Market 2016-2021
6.6 Middle East and Africa Gene Therapy On Cardiovascular Disease Market 2016-2021
7 North America
7.1 North America Gene Therapy On Cardiovascular Disease Market by Country 2016-2021
7.1.1 North America Gene Therapy On Cardiovascular Disease Sales by Country
7.1.2 North America Gene Therapy On Cardiovascular Disease Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico
8 Europe
8.1 Europe Gene Therapy On Cardiovascular Disease Market by Country 2016-2021
8.1.1 Europe Gene Therapy On Cardiovascular Disease Sales by Country
8.1.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain
9 Asia Pacific
9.1 Asia Pacific Gene Therapy On Cardiovascular Disease Market by Country 2016-2021
9.1.1 Asia Pacific Gene Therapy On Cardiovascular Disease Sales by Country
9.1.2 Asia Pacific Gene Therapy On Cardiovascular Disease Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia
10 South America
10.1 South America Gene Therapy On Cardiovascular Disease Market by Country 2016-2021
10.1.1 South America Gene Therapy On Cardiovascular Disease Sales by Country
10.1.2 South America Gene Therapy On Cardiovascular Disease Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Gene Therapy On Cardiovascular Disease Market by Country 2016-2021
11.1.1 Middle East and Africa Gene Therapy On Cardiovascular Disease Sales by Country
11.1.2 Middle East and Africa Gene Therapy On Cardiovascular Disease Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa
12 Key Participants Company Information
12.1 Sunway Biotech
12.1.1 Sunway Biotech Company Information
12.1.2 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.1.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 Sunway Biotech Key Development
12.2 Spark Therapeutics
12.2.1 Spark Therapeutics Company Information
12.2.2 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.2.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Spark Therapeutics Key Development
12.3 SIBIONO
12.3.1 SIBIONO Company Information
12.3.2 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.3.3 SIBIONO Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 SIBIONO Key Development
12.4 Sarepta Therapeutics
12.4.1 Sarepta Therapeutics Company Information
12.4.2 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Sarepta Therapeutics Key Development
12.5 Orchard Therapeutics
12.5.1 Orchard Therapeutics Company Information
12.5.2 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.5.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Orchard Therapeutics Key Development
12.6 Novartis
12.6.1 Novartis Company Information
12.6.2 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.6.3 Novartis Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 Novartis Key Development
12.7 Human Stem Cells Institute
12.7.1 Human Stem Cells Institute Company Information
12.7.2 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.7.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 Novartis Key Development
12.9 bluebird bio
12.9.1 bluebird bio Company Information
12.9.2 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 bluebird bio Key Development
12.8 Gilead Sciences
12.8.1 Gilead Sciences Company Information
12.8.2 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.8.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 Gilead Sciences Key Development
12.11 AnGes
12.11.1 AnGes Company Information
12.11.2 AnGes Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.11.3 AnGes Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.11.4 AnGes Key Development
12.12 Amgen
12.12.1 Amgen Company Information
12.12.2 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.12.3 Amgen Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.12.4 Amgen Key Development
12.13 Alnylam Pharmaceuticals
12.13.1 Alnylam Pharmaceuticals Company Information
12.13.2 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.13.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.13.4 Alnylam Pharmaceuticals Key Development
12.14 Akcea Therapeutics
12.14.1 Akcea Therapeutics Company Information
12.14.2 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
12.14.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
12.14.4 Akcea Therapeutics Key Development
13 Global Gene Therapy On Cardiovascular Disease Market Forecast by Region by Type and by Application
13.1 Global Gene Therapy On Cardiovascular Disease Sales, Revenue Forecast 2022-2027
13.2 Global Gene Therapy On Cardiovascular Disease Forecast by Regions
13.2.1 Global Gene Therapy On Cardiovascular Disease Sales Forecast by Region 2022-2027
13.2.2 Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Region 2022-2027
13.3 Global Gene Therapy On Cardiovascular Disease Forecast by Type
13.3.1 Global Gene Therapy On Cardiovascular Disease Sales Forecast by Type 2022-2027
13.3.2 Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Type 2022-2027
13.3.3 Global Gene Therapy On Cardiovascular Disease Price Forecast by Type 2022-2027
13.4 Global Gene Therapy On Cardiovascular Disease Forecast by Application
13.4.1 Global Gene Therapy On Cardiovascular Disease Sales Forecast by Application 2022-2027
13.4.2 Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Application 2022-2027
13.4.3 Global Gene Therapy On Cardiovascular Disease Price Forecast by Application 2022-2027
14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer
List of Tables
Table 1: Global Gene Therapy On Cardiovascular Disease Production Specifications
Table 2: Drivers in Gene Therapy On Cardiovascular Disease Market
Table 3: Restraints Gene Therapy On Cardiovascular Disease Market
Table 4: Opportunity in Gene Therapy On Cardiovascular Disease Market
Table 5: Comparion of Alternative and Gene Therapy On Cardiovascular Disease
Table 6: Gene Therapy On Cardiovascular Disease Raw Materials Key Suppliers List
Table 7: Gene Therapy On Cardiovascular Disease Distributors List
Table 8: Gene Therapy On Cardiovascular Disease Major Buyers in Application One
Table 9: Gene Therapy On Cardiovascular Disease Major Buyers in Application Two
Table 10: Gene Therapy On Cardiovascular Disease Major Buyers in Application Three
Table 11: Global Gene Therapy On Cardiovascular Disease Sales (K Units) by Type 2016-2021
Table 12: Global Gene Therapy On Cardiovascular Disease Sales Market Share by Type 2016-2021
Table 13: Global Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Type 2016-2021
Table 14: Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type 2016-2021
Table 15: Global Gene Therapy On Cardiovascular Disease Price by Type 2016-2021
Table 16: Global Gene Therapy On Cardiovascular Disease Sales (K Units) by Application 2016-2021
Table 17: Global Gene Therapy On Cardiovascular Disease Sales Market Share by Application 2016-2021
Table 18: Global Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Application 2016-2021
Table 19: Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application 2016-2021
Table 20: Global Gene Therapy On Cardiovascular Disease Price by Application 2016-2021
Table 21: Global Gene Therapy On Cardiovascular Disease Sales (K Units) by Region 2016-2021
Table 22: Global Gene Therapy On Cardiovascular Disease Sales Market Share by Region 2016-2021
Table 23: Global Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Region 2016-2021
Table 24: Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region 2016-2021
Table 25: North America Gene Therapy On Cardiovascular Disease Sales (K Units) by Country 2016-2021
Table 26: North America Gene Therapy On Cardiovascular Disease Sales Market Share by Country 2016-2021
Table 27: North America Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Country 2016-2021
Table 28: North America Gene Therapy On Cardiovascular Disease Revenue Market Share by Country 2016-2021)
Table 29: Europe Gene Therapy On Cardiovascular Disease Sales (K Units) by Country 2016-2021
Table 30: Europe Gene Therapy On Cardiovascular Disease Sales Market Share by Country 2016-2021
Table 31: Europe Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Country 2016-2021
Table 32: Europe Gene Therapy On Cardiovascular Disease Revenue Market Share by Country 2016-2021)
Table 33: Asia Pacific Gene Therapy On Cardiovascular Disease Sales (K Units) by Country 2016-2021
Table 34: Asia Pacific Gene Therapy On Cardiovascular Disease Sales Market Share by Country 2016-2021
Table 35: Asia Pacific Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Country 2016-2021
Table 36: Asia Pacific Gene Therapy On Cardiovascular Disease Revenue Market Share by Country 2016-2021)
Table 37: South America Gene Therapy On Cardiovascular Disease Sales (K Units) by Country 2016-2021
Table 38: South America Gene Therapy On Cardiovascular Disease Sales Market Share by Country 2016-2021
Table 39: South America Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Country 2016-2021
Table 40: South America Gene Therapy On Cardiovascular Disease Revenue Market Share by Country 2016-2021)
Table 41: Middle East and Africa Gene Therapy On Cardiovascular Disease Sales (K Units) by Country 2016-2021
Table 42: Middle East and Africa Gene Therapy On Cardiovascular Disease Sales Market Share by Country 2016-2021
Table 43: Middle East and Africa Gene Therapy On Cardiovascular Disease Revenue (Million USD) by Country 2016-2021
Table 44: Middle East and Africa Gene Therapy On Cardiovascular Disease Revenue Market Share by Country 2016-2021)
Table 45 Sunway Biotech Company Information
Table 46 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 47 Sunway Biotech Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 48 Spark Therapeutics Company Information
Table 49 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 50 Spark Therapeutics Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 51 SIBIONO Company Information
Table 52 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 53 SIBIONO Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 54 Sarepta Therapeutics Company Information
Table 55 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 56 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 57 Orchard Therapeutics Company Information
Table 58 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 59 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 60 Novartis Company Information
Table 61 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 62 Novartis Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 63 Human Stem Cells Institute Company Information
Table 64 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 65 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 66 Gilead Sciences Company Information
Table 67 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 68 Gilead Sciences Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 69 bluebird bio Company Information
Table 70 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio, Specification and Application
Table 71 bluebird bio Gene Therapy On Cardiovascular Disease Sales, Price, Revenue and Gross Margin (2019-2021)
Table 72: Global Gene Therapy On Cardiovascular Disease Sales (K Units) Forecast by Region (2022-2027)
Table 73: Global Gene Therapy On Cardiovascular Disease Sales Market Share Forecast by Region (2012-2027)
Table 74: Global Gene Therapy On Cardiovascular Disease Revenue (Million USD) Forecast by Region (2022-2027)
Table 75: Global Gene Therapy On Cardiovascular Disease Revenue Market Share Forecast by Region (2022-2027)
Table 76: Global Gene Therapy On Cardiovascular Disease Sales (K Units) Forecast by Type (2022-2027)
Table 77: Global Gene Therapy On Cardiovascular Disease Sales Market Share Forecast by Type (2012-2027)
Table 78: Global Gene Therapy On Cardiovascular Disease Revenue (Million USD) Forecast by Type (2022-2027)
Table 79: Global Gene Therapy On Cardiovascular Disease Revenue Market Share Forecast by Type (2022-2027)
Table 80: Global Gene Therapy On Cardiovascular Disease Sales (K Units) Forecast by Applicaion (2022-2027)
Table 81: Global Gene Therapy On Cardiovascular Disease Sales Market Share Forecast by Application (2012-2027)
Table 82: Global Gene Therapy On Cardiovascular Disease Revenue (Million USD) Forecast by Application (2022-2027)
Table 83: Global Gene Therapy On Cardiovascular Disease Revenue Market Share Forecast by Application (2022-2027)
Tables and Figures
List of Figures
Figure 1: Gene Therapy On Cardiovascular Disease Picture
Figure 2: Global Gene Therapy On Cardiovascular Disease Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Gene Therapy On Cardiovascular Disease Supply Chain Analysis
Figure 5: Gene Therapy On Cardiovascular Disease Manufacturing Cost Structure Analysis
Figure 6: Product Picture of Viral Gene Therapy
Figure 7: Product Picture of Non-Viral Gene Therapy
Figure 8: Global Gene Therapy On Cardiovascular Disease Sales Market Share by Type, 2020
Figure 9: Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type, 2020
Figure 10: Gene Therapy On Cardiovascular Disease in Heart Disease
Figure 11: Global Gene Therapy On Cardiovascular Disease Market: Heart Disease 2016-2021
Figure 12: Gene Therapy On Cardiovascular Disease in Vascular Disease
Figure 13: Global Gene Therapy On Cardiovascular Disease Market: Vascular Disease 2016-2021
Figure 14: Global Gene Therapy On Cardiovascular Disease Sales Market Share by Application, 2020
Figure 15: Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application, 2020
Figure 16: Global Gene Therapy On Cardiovascular Disease Sales Market Share by Region 2016-2021
Figure 17: Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region 2016-2021
Figure 18: North America Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 19: North America Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 20: Europe Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 21: Europe Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 23: Asia Pacific Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 24: South America Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 25: South America Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 26: Middle East and Africa Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 27: Middle East and Africa Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 28: North America Gene Therapy On Cardiovascular Disease Sales Market Share by Country, 2020
Figure 29: North America Gene Therapy On Cardiovascular Disease Revenue Market Share by Country, 2020
Figure 30: United States Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 31: United States Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 32: Canada Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 33: Canada Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 34: Mexico Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 35: Mexico Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 36: Europe Gene Therapy On Cardiovascular Disease Sales Market Share by Country, 2020
Figure 37: Europe Gene Therapy On Cardiovascular Disease Revenue Market Share by Country, 2020
Figure 38: Germany Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 39: Germany Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 40: France Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 41: France Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 42: UK Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 43: UK Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 44: Italy Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 45: Italy Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 46: Russia Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 46: Russia Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 47: Spain Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 48: Spain Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 49: Asia Pacific Gene Therapy On Cardiovascular Disease Sales Market Share by Country, 2020
Figure 50: Asia Pacific Gene Therapy On Cardiovascular Disease Revenue Market Share by Country, 2020
Figure 51: China Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 52: China Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 53: Japan Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 54: Japan Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 55: Korea Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 56: Korea Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 57: Southeast Asia Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 58: Southeast Asia Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 59: India Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 60: India Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 61: Australia Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 62: Australia Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 63: South America Gene Therapy On Cardiovascular Disease Sales Market Share by Country, 2020
Figure 64: South America Gene Therapy On Cardiovascular Disease Revenue Market Share by Country, 2020
Figure 65: Brazil Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 66: Brazil Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 67: Argentina Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 68: Argentina Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 69: Colombia Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 70: Colombia Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 71: Middle East and Africa Gene Therapy On Cardiovascular Disease Sales Market Share by Country, 2020
Figure 72: Middle East and Africa Gene Therapy On Cardiovascular Disease Revenue Market Share by Country, 2020
Figure 73: Turkey Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 74: Turkey Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 75: Saudi Arabia Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 76: Saudi Arabia Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 77: South Africa Gene Therapy On Cardiovascular Disease Sales (K Units) Status 2016-2021
Figure 78: South Africa Gene Therapy On Cardiovascular Disease Revenue (Million USD) Status 2016-2021
Figure 79: Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 80: Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 81: SIBIONO Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 82: Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 83: Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 84: Novartis Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 85: Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 86: Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 87: bluebird bio Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 88: Biogen Gene Therapy On Cardiovascular Disease Revenue Market Share Globally (2019-2021)
Figure 89: Global Gene Therapy On Cardiovascular Disease Sales (K Units) Forecast (2022-2027)
Figure 90: Global Gene Therapy On Cardiovascular Disease Sales (K Units) Forecast (2022-2027)
Reason to Buy
- Current and future of Medical Devices & Consumables Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Medical Devices & Consumables Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Medical Devices & Consumables Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Medical Devices & Consumables Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets